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Purpose: The purpose of this multicentre prospective study was to investigate the signiﬁcance of the radi-
ation dose in the major and minor salivary glands, and other pre-treatment and treatment factors, with
regard to the development of patient-rated xerostomia and sticky saliva among head and neck cancer
(HNC) patients treated with primary (chemo-) radiotherapy ((CH)RT).
Methods and materials: The study population was composed of 167 consecutive HNC patients treated
with three-dimensional conformal (3D-CRT) (CH) RT. The primary endpoint was moderate to severe xero-
stomia (XER6m) as assessed by the EORTC QLQ-H&N35 at 6 months after completing (CH)RT. The second-
ary endpoint was moderate to severe sticky saliva at 6 months (STIC6 m). All organs at risk (OARs)
potentially involved in salivary function were delineated on planning-CT, including the parotid, subman-
dibular and sublingual glands and the minor glands in the soft palate, cheeks and lips. Patients with mod-
erate to severe xerostomia or sticky saliva at baseline were excluded. The optimum number of variables
for a multivariate logistic regression model was determined using a bootstrapping method.
Results: The multivariate analysis showed the mean parotid dose, age and baseline xerostomia (none ver-
sus a bit) to be the most important predictors for XER6m. The risk of developing xerostomia increased
with age and was higher when minor baseline xerostomia was present in comparison with patients with-
out any xerostomia complaints at baseline. Model performance was good with an area under the curve
(AUC) of 0.82.
For STIC6m, the mean submandibular dose, age, the mean sublingual dose and baseline sticky saliva
(none versus a bit) were most predictive for sticky saliva. The risk of developing STIC6 m increased with
age and was higher when minor baseline sticky saliva was present in comparison with patients without
any sticky saliva complaints at baseline. Model performance was good with an AUC of 0.84.
Conclusions: Dose distributions in the minor salivary glands in patients receiving 3D-CRT have limited
signiﬁcance with regard to patient-rated symptoms related to salivary dysfunction. Besides the parotid
and submandibular glands, only the sublingual glands were signiﬁcantly associated with sticky saliva.
In addition, reliable risk estimation also requires information from other factors such as age and baseline
subjective scores. When these selected factors are included in predictive models, instead of only dose vol-
ume histogram parameters, model performance can be improved signiﬁcantly.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 105 (2012) 86–93In patients with head and neck cancer (HNC), radiotherapy in-
cludes irradiation of parts of the salivary glands. This might result
in salivary dysfunction and subsequent xerostomia, which is one ofdiation Oncology, University
roningen, The Netherlands.
er the Elsevier OA license.the most frequently reported side effects of radiation treatment in
the head and neck area [1–6]. In addition, salivary dysfunction may
lead to additional effects, such as sensation of a dry mouth, altered
taste, swallowing problems and speech problems which have a sig-
niﬁcant impact on the general dimensions of health-related quality
of life (HRQoL) [1,7–15].
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salivary glands and different time points [16–22]. The parotid
and submandibular glands are responsible for the main stimulated
saliva production and the production of saliva at rest, while during
sleep saliva is predominantly produced by the sublingual and the
minor salivary glands located at the inner surface of the lower
lip, upper lip and both cheeks and the submandibular glands
[18]. In contrast, during sleep the saliva production of the parotid
glands declines almost to zero.
Until now, most investigators mainly focused on the univariate
relationship between parotid gland dose and stimulated and/or
unstimulated parotid salivary ﬂow [23–25]. However, the develop-
ment of xerostomia as reported by patients most likely depends on
a variety of prognostic factors, such as radiation dose distributions
in the salivary glands as well as demographic, tumour-related and
treatment-related factors [26]. Therefore, large prospective cohort
studies are required to determine which factors are most impor-
tant in predicting patient-rated xerostomia after a curative course
of radiation in which all these factors can also be taken into
account.
The study reported on in this paper is part of the ALLEGRO pro-
ject (early and late health risks to normal/healthy tissues from the
use of existing and emerging techniques for radiation therapy)
which is funded by the European Union [27]. The three general
objectives of the ALLEGRO project are: (1) investigation of the mag-
nitude and distribution of radiation doses in normal tissues (from
all causes, adjusted where necessary for biological effect) received
in treatments with current and emerging radiation technologies;
(2) investigation of the risk of second cancers from the radiation
exposure of normal tissues, and: (3) modelling of the risk of normal
tissue damage in common cancer treatments and estimation of the
beneﬁcial effects of emerging radiation delivery techniques (e.g.,
radiation with protons).
In the work package regarding normal tissue complication
probability (NTCP) modelling, a 4-step approach is applied. Step
1 includes the development of predictive models among patients
treated with 3D conformal radiotherapy (3D-CRT). In step 2 the
validity of these predictive models will be tested among patients
treated with intensity modulated radiotherapy (IMRT). In step 3,
we will investigate as to whether new radiation techniques could
be further optimized in terms of physical dose distributions using
the most relevant dose volume histogram (DVH) parameters from
the predictive models from steps 1 and 2, also referred to in silico
planning comparative (ISPC) studies. Finally, the aim is to estimate
the potential beneﬁt of these new techniques by combining the re-
sults of the predictive models and the ISPC-studies in order to see
if, and to what extent, differences in physical dose distributions
translate into reductions in NTCP-values.
The main objective of the current paper was to report on the re-
sults of the ﬁrst step, i.e., the development of predictive models for
patient-rated symptoms related to salivary dysfunction (i.e., xero-
stomia and sticky saliva) taking into account dose distributions in
all salivary glands (i.e., major as well as minor salivary glands) as
well as taking into account other potential clinical and treat-
ment-related determinants.Methods and materials
The standardised follow up program
Since 1997, all patients referred for radiotherapy for HNC to the
Department of Radiation Oncology of the VU University Medical
Center, Amsterdam, the Netherlands (VUMC) were included in a
standardised follow up program (SFP). Since March 2007, the same
SFP was established at the department of Radiation Oncology of
the University Medical Center Groningen, Groningen, The Nether-lands (UMCG). Until the end of 2007, the majority of patients were
treated with 3D-CRT, while since 2008 patients were increasingly
treated with IMRT. The SFP includes a prospective evaluation of
toxicity and HRQoL on a routine basis, prior to, during and at reg-
ular intervals after curative (chemo-) radiotherapy ((CH)RT).
HRQoL was assessed using the EORTC QLQ-C30 and the additional
head and neck cancer module, the EORTC QLQ-H&N35 at baseline,
6 weeks post-treatment and at 6 month intervals thereafter [28–
30].Patients
To be included in the analysis, patients had to fulﬁl the follow-
ing eligibility criteria: (1) HNC originating in the oral cavity, oro-
pharynx, larynx, hypopharynx or nasopharynx; (2) treated with
curative 3D-CRT either alone or in combination with chemother-
apy or cetuximab; (3) no previous surgery, radiotherapy and/or
chemotherapy; (4) no previous malignancies; (5) no distant metas-
tases; (6) planning-CT and 3D-dose distributions available in DI-
COM-format, and: (7) HRQoL assessments available prior to and
6 months after completion of (CH)RT. Eventually, the prospective
cohort used for this analysis was composed of 205 patients who
fulﬁlled all these eligibility criteria.Endpoints
For the evaluation of patient-rated xerostomia and sticky saliva,
the EORTC QLQ-H&N35 questionnaire was used 6 months after
treatment. Six months was chosen because former studies indi-
cated that after 3D-CRT the assessment on this time point is pre-
dictive for subsequent time points [5,11,31]. For all questions,
including those regarding xerostomia and sticky saliva, a 4-point
Likert scale was used varying from none, a bit, quite a bit and a
lot. For the purpose of this study, the primary endpoint was de-
ﬁned as moderate to severe xerostomia at 6 months after comple-
tion of radiotherapy, which corresponds with the two highest
scores on the 4-point scale. Patients with moderate to severe xero-
stomia or sticky saliva at baseline were excluded from the analysis.
This was done, as we were primarily interested in xerostomia and
sticky saliva induced by radiation treatment itself. Thirty-three pa-
tients suffered frommoderate to severe xerostomia at baseline and
were excluded for further analysis. From these 172 patients, 165
(96%) completed the EORTC QLQ HN35 at 6 months after treatment
and were included in the analysis.
Similarly, for the analysis of sticky saliva, only those with no or
minimal complaints at baseline were included. Twenty-eight of all
205 included patients suffered from moderate to severe sticky sal-
iva and were excluded from further analysis. From the remaining
177 patients, 167 (94%) completed the EORTC QLQ-HN35 at
6 months after treatment.
The majority of patients were males (76%) and the mean age of
the study population was 63.8 years, ranging from 41 to 92 years
for patients included in both the xerostomia and sticky saliva anal-
yses. Most of the patients were treated with radiotherapy alone
(78%). The demographic and tumour characteristics of these two
study populations are listed in Table 1.Treatment
Radiotherapy was delivered using megavoltage equipment
(6 MV linear accelerator). In all patients, a planning CT scan was
made in supine position. All patients were treated with 3D-CRT,
without attempts to spare the salivary glands. Patient position
was ﬁxed with a ﬁve point individual thermoplastic mask (Posi-
cast thermoplastics, CIVCO) in combination with a standard head
support (Posiﬁx supine headrest, CIVCO). Position veriﬁcation
Table 1
Demographic and disease-related characteristics for the patients included in the xerostomia (165) and sticky saliva analysis (n = 167).
Characteristics Xerostomia (n = 165) % Sticky saliva (n = 167) %
Sex
Male 126 76 124 74
Female 39 24 43 26
Age
<65 101 61 99 59
>65 64 39 68 41
Chemotherapy
Yes 36 22 36 22
No 129 78 131 78
Tumour classiﬁcation
T0 5 3 6 4
T1 27 16 28 17
T2 85 52 87 52
T3 25 15 22 13
T4 23 14 24 14
Node classiﬁcation
N0 113 69 118 70
N1 10 6 9 5
N2a 5 3 5 3
N2b 17 10 16 10
N2c 16 10 16 10
N3 4 2 3 2
Site
Oropharynx 47 29 46 28
Sinuses and nasopharynx 6 4 7 4
Hypopharynx 10 6 9 5
Larynx 98 59 100 60
Miscellaneous 4 2 5 3
Bilateral neck irradiation
Yes 111 67 110 66
No 54 33 57 34
Medical centre
UMCG 43 26 43 26
VUMC 122 74 124 74
88 Multivariate NTCP modelling for patient-related xerostomiawas carried out by using a shrinking action level correction proto-
col (SAL-protocol), using an electronic portal imaging device
(EPID).
Patients with early glottic carcinoma were treated with a frac-
tional dose of 2.5 Gy (5 times/week) up to a total dose of 60 Gy
in 5 weeks or with a fraction dose of 2.0 Gy (5 or 6 times/week)
up to a total dose of 66 Gy. These patients were only irradiated
at the primary site.
Patients treated with concomitant CHRT were treated with con-
ventional fractionation (2.0 Gy per fraction, 5 times per week up to
70 Gy in 7 weeks). In case of primary radiotherapy of the more ad-
vanced cases, which were considered not eligible for CHRT, an
accelerated schedule with concomitant boost technique was used,
either or not combined with cetuximab. These patients were gen-
erally treated with 6 fractions per week with a second fraction on
Friday afternoon with a minimum interval of 6 h, up to a total dose
of 70 Gy in 6 weeks. Most patients received bilateral elective irra-
diation of the neck nodes to a total dose of 46 Gy and a boost on
the primary tumour and pathological lymph nodes to a total dose
of 70 Gy. In some cases, radiotherapy only with conventional frac-
tionation was used.Contouring of organs at risk
Organs at risk (OARs) potentially involved in salivary function
related symptoms were delineated according to the guidelines
for OARs potentially involved in radiation-induced salivary dys-
function and xerostomia as described by Van de Water et al.
[26], including the parotid, submandibular and sublingual glands,
as well as the minor salivary glands located in the soft palate,
the inner surface of the lower and upper lip and the minor salivary
glands in the inner surface of the cheeks. All OARs were delineatedby an expert in head and neck radiation (JL). For this purpose, all
planning-CT scans were transferred to the Pinnacle Treatment
Planning System (TPS) (version 8.0 h, Philips Radiation Oncology
Systems, Fitchburg, WI). After completing OARs contouring, all
data were transferred to the VODCA platform (VODCA Company:
viewer version 4.2.2. and database version 4.1.1). The VODCA plat-
form is a software program which allows for dose distribution
evaluation of different TPS’s.Dose distribution calculations
The dose distributions from the original treatment planning
systems (Pinnacle, Masterplan, Eclipse, CadPlan) used were trans-
ferred to the VODCA platform in DICOM format. The original dose
distributions in all aforementioned potential OARs could be recon-
structed and DVHs could be generated.Statistics
For the development of the predictive models for patient-rated
xerostomia and sticky saliva, a multivariate logistic regression
analysis was used with an extended bootstrapping technique and
forward variable selection as described by El Naqa et al. [32]. In
contrast to the El Naqa method, our method uses the likelihood cri-
terion, instead of correlation measures. The average likelihood is
calculated over all test datasets for each combination of variables.
The model which gives the highest average likelihood was selected
as the most predictive model.
Before carrying out the regression analysis, a correlation matrix
was produced to check for high correlations between potential
prognostic determinants, in particular between DVH-parameters.
In case of Pearson correlation coefﬁcients P0.8 between potential
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gle variable to avoid the problem of multicollinearity which may
negatively affect the generalisability of the model. Finally, all
DVH data were transferred to MATLAB (version R2009b) and con-
nected to all other potential pre-treatment prognostic factors for
each individual patient.
The variables initially included in the multivariate model are
listed in Table 2. After reducing the number of variables based on
the correlation coefﬁcient analysis, a multivariate logistic regres-
sion with forward selection and an extended bootstrapping tech-
nique was carried out. We used 2000 bootstraps for each
analysis. For every model order, the average likelihood of predic-
tions was calculated and the number of variables selected with
the highest average likelihood was selected for the deﬁnite predic-
tive model for patient-rated xerostomia and sticky saliva.
After selecting the combination of variables with the highest
performance in MATLAB, the analysis was repeated in SPSS for
windows (version 16.0; SPSS, Chigaco, IL) using exactly the same
dataset and selected variables. Adjusted Odd’s ratios (ORs) and
95% conﬁdence intervals (95% CI) were calculated in SPSS for the
selected variables in the model. For each patient, predictive values
(i.e., NTCP values) were calculated for each set of prognostic vari-
ables based on the regression coefﬁcients according to the formula:Table 2
Univariate logistic regression coefﬁcients for all possible predictors for xerostomia and sti
Predictor Xerostomia
b OR 95% CI p
Mean dose parotid glands (Gy) 0.06 1.06 1.04–1.08 <
Mean dose submandibular glands (Gy) 0.05 1.05 1.03–1.07 <
Mean dose sublingual glands (Gy) 0.02 1.02 1.01–1.04 <
Mean dose cheeks (Gy) 0.04 1.04 1.02–1.07 <
Mean dose inner surface lower lip (Gy) 0.02 1.02 1.00–1.05 0
Mean dose inner surface upper lip (Gy) 0.03 1.03 1.00–1.07 0
Mean dose soft palate (Gy) 0.03 1.03 1.02–1.05 <
Sex 0.24 1.27 0.67–2.40 0
Age 0.01 1.01 0.98–1.04 0
Chemotherapy 0.93 2.53 1.15–5.58 0
Accelerated radiotherapy 0.29 0.75 0.40–1.42 0
Baseline xerostomia score 1.01 2.75 1.39–5.47 <
Baseline sticky saliva score 0.59 1.81 1.01–3.23 0
Bilateral neck irradiation 1.80 6.06 2.90–12.66 <
Medical centre (UMCG vs. VUMC) 1.09 2.98 1.43–6.21 <
Mean 
dose
Max 
dose
V5 V10 V20 V40
Mean dose 1.00 0.89 0.88 0.90 0.95 0.97
maximum dose 0.89 1.00 0.91 0.92 0.90 0.85
V5 0.88 0.91 1.00 0.99 0.95 0.87
V10 0.90 0.92 0.99 1.00 0.97 0.91
V20 0.95 0.90 0.95 0.97 1.00 0.96
V40 0.97 0.85 0.87 0.91 0.96 1.00
V60 0.83 0.63 0.57 0.61 0.69 0.80
Mean dose 0.81 0.74 0.75 0.75 0.78 0.78
maximum dose 0.71 0.83 0.77 0.75 0.73 0.67
V5 0.79 0.83 0.90 0.89 0.86 0.79
V10 0.74 0.76 0.84 0.82 0.80 0.74
V20 0.73 0.71 0.77 0.77 0.77 0.75
V40 0.76 0.67 0.71 0.72 0.76 0.79
V60 0.63 0.49 0.46 0.49 0.55 0.63
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Fig. 1. Paerson correlation coefﬁcients between the ipsi- and contralateral parotid gland
colored in red. Very strong correlations within and between ipsi- and contralateral saliva
and contralateral glands, to avoid multicollinearity.NTCP ¼ ð1þ eSÞ1; in which
S ¼ b0 þ
Xn
i¼1
bi  xi
In SPSS, model performance was then determined by calculating the
area under the curves (AUC) based on receiver operating
characteristics.
Results
Variable reduction and dose distribution procedure
In order to reduce the number of variables in the model, we ﬁrst
produced a correlation matrix to identify DVH-parameters of all
OARs that were strongly correlated (i.e., Pearson correlation coefﬁ-
cient P0.8) (Fig. 1). There was a very strong correlation between
all DVH parameters within each OAR and the mean dose of that
OAR. Therefore, we decided to only include the mean doses of all
OARs in the multivariate model to prevent the problem of multi-
collinearity. In addition, we also found a very strong correlation be-
tween the mean dose in the ipsilateral and contralateral parotid,
submandibular and sublingual glands and the ipsi- and contralat-
eral glands in the cheek (Pearson r > 0.8). Therefore, we decidedcky saliva.
Sticky saliva
-value AUC b OR 95% CI p-value AUC
0.01 0.79 0.03 1.03 1.02–1.05 <0.01 0.69
0.01 0.75 0.04 1.04 1.02–1.05 <0.01 0.68
0.01 0.72 0.00 1.00 0.99–1.01 0.67 0.57
0.01 0.72 0.00 1.00 0.99–1.02 0.77 0.55
.07 0.67 0.13 0.99 0.97–1.01 0.21 0.51
.06 0.65 0.15 0.99 0.96–1.01 0.30 0.52
0.01 0.75 0.01 1.01 1.00–1.02 0.06 0.61
.46 0.56 0.31 1.37 0.68–2.74 0.38 0.53
.54 0.51 0.03 1.03 1.00–1.06 0.06 0.57
.02 0.58 0.21 1.24 0.59–2.59 0.57 0.52
.38 0.53 0.02 1.02 0.54–1.91 0.96 0.50
0.01 0.61 0.63 1.87 1.15–3.04 0.01 0.61
.05 0.57 0.94 2.57 1.27–5.17 <0.01 0.59
0.01 0.68 1.97 7.15 3.19–16.01 <0.01 0.69
0.01 0.60 1.54 4.67 2.0–10.9 <0.01 0.63
V60 Mean 
dose
Max 
dose
V5 V10 V20 V40 V60
0.83 0.81 0.71 0.79 0.74 0.73 0.76 0.63
0.63 0.74 0.83 0.83 0.76 0.71 0.67 0.49
0.57 0.75 0.77 0.90 0.84 0.77 0.71 0.46
0.61 0.75 0.75 0.89 0.82 0.77 0.72 0.49
0.69 0.78 0.73 0.86 0.80 0.77 0.76 0.55
0.80 0.78 0.67 0.79 0.74 0.75 0.79 0.63
1.00 0.64 0.49 0.52 0.49 0.54 0.62 0.76
0.64 1.00 0.89 0.85 0.91 0.96 0.97 0.75
0.49 0.89 1.00 0.87 0.91 0.90 0.84 0.56
0.52 0.85 0.87 1.00 0.96 0.89 0.82 0.50
0.49 0.91 0.91 0.96 1.00 0.95 0.89 0.54
0.54 0.96 0.90 0.89 0.95 1.00 0.97 0.63
0.62 0.97 0.84 0.82 0.89 0.97 1.00 0.73
0.76 0.75 0.56 0.50 0.54 0.63 0.73 1.00
Partoid gland contralateral
. Part of the correlation matrix. Strong correlations between two variables (>0.8) are
ry glands were observed and, therefore, analyses were carried out with pairs of ipsi-
90 Multivariate NTCP modelling for patient-related xerostomiato use the mean dose in these ipsi- and contralateral glands as one
single variable.
Appendix A includes the correlation matrix of all determinants
entered in the multivariate analysis, the correlations between the
mean dose to the parotid glands and submandibular glands was
above 0.80 and also Pearson correlation between the parotid
glands and dose to the soft palate was beyond 0.80 (0.87).Prevalences of patient rated xerostomia and sticky saliva
At 6 months after treatment, 52% of the patients reported mod-
erate to severe xerostomia. After 12, 18 and 24 months, 38%, 35%
and 35%, respectively, reported moderate to severe xerostomia.
At 6 months after treatment, 43% of the patients reported moder-
ate to severe sticky saliva. At 12, 18 and 24 months after treatment,
28%, 33% and 27%, respectively reported moderate/severe sticky0.53
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Fig. 2. Average likelihood for bootstrapping technique for each number of selected
variables in the multivariate logistic regression analysis for each model order. Best
model performance is observed with a model order with the highest average of total
likelihood of bootstrap predictions. For, respectively, xerostomia and sticky saliva
the best model performance was seen with three and four selected variables.
Table 3
Distributions of the mean dose for the selected organs at risk for the patient-rated xerostom
(submandibular glands and sublingual glands). The analysis for patient-rated xerostomia
Dose (Gy) Mean dose parotid glands (n = 165) Mean dose subman
Number of patients % Number of patients
0–10 45 27 25
10–20 9 5 13
20–30 35 21 9
30–40 29 18 11
40–50 13 8 29
50–60 11 7 19
60–70 23 14 31
>70 0 0 30
Table 4
Multivariate logistic regression model for patient-rated xerostomia and sticky saliva 6 mo
Predictor b
Xerostomia model
Mean dose parotid glands (Gy) 0.066
Age (years) 0.050
Baseline xerostomia score (none vs. a bit) 0.916
Constant 5.27
Sticky saliva model
Mean dose submandibular glands (Gy) 0.091
Age (years) 0.107
Mean dose sublingual glands (Gy) 0.041
Baseline sticky saliva score (none vs. a bit) 1.218
Constant 10.70saliva. Additional analysis showed that the 6 month assessments
were very predictive for these endpoints at subsequent time
points. Therefore, we decided to use the 6 months assessments as
primary outcome measure for the current analysis.Xerostomia
In the univariate analysis, the mean dose in the parotid, sub-
mandibular, sublingual glands, the minor glands in the cheeks,
the minor glands in the soft palate, chemotherapy, bilateral neck
irradiation and baseline xerostomia and sticky saliva score (none
versus a bit) and the treatment centre were signiﬁcantly associated
with patient-rated xerostomia 6 months after treatment (Table 2).
Average likelihood of bootstrap prediction in the multivariate lo-
gistic regression analysis was optimal with a model consisting of
three variables (Fig. 2). Increasing the number of variables to four
did not further increase the average likelihood of the model com-
pared to the 3-factor model.
The three variables selected were the mean dose to the parotid
glands, age and baseline xerostomia (none versus a bit). AUC for
this 3-factor model was 0.82 (95% CI 0.76–0.89). This model de-
scribes the relation for a mean dose of the parotid glands ranged
from low dose to high dose (Table 3). The ORs for each of the 3 se-
lected variables are shown in Table 4. The NTCP-value for each
individual patient can be calculated by the following logistic
regression formula:NTCP ¼ ð1þ eSÞ1; in which
S ¼ 5:27þ ðmean dose parotid gland  0:066Þ
þ ðage  0:050Þ þ ðbaseline xerostomia score  0:916ÞAlternatively, the NTCP-value for each individual patient can be
determined using the nomogram for xerostomia in Appendix B.ia NTCP model (parotid glands) and for the NTCP model for patient-rated sticky saliva
included 165 patients and for sticky saliva 167 patients.
dibular glands (n = 167) Mean dose sublingual glands (n = 167)
% Number of patients %
15 80 48
8 12 7
5 7 4
7 11 7
17 17 10
11 14 8
19 19 11
18 7 4
nths after treatment.
p-value Odds ratio 95% CI
<0.001 1.07 1.05–1.09
0.014 1.05 1.01–1.09
0.024 2.50 1.13–5.55
<0.001
<0.001 1.10 1.06–1.13
<0.001 1.11 1.06–1.17
<0.001 0.96 0.94–0.98
0.006 3.38 1.42–8.06
<0.001
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In the univariate analysis, the mean dose to the parotid and sub-
mandibular glands, bilateral neck irradiation, baseline sticky saliva
score and xerostomia score (none versus a bit) and the treatment
centre were signiﬁcantly associated with patient-rated sticky sali-
va 6 months after treatment (Table 2). In the multivariate analysis
with bootstrapping, the average likelihood was maximal with a
model consisting of 4 variables (Fig. 2).
The four factor model included the following variables: the
mean dose to the submandibular glands, age, the mean dose in
the sublingual glands and sticky saliva at baseline. AUC for this
four factor model was 0.84 (95% CI 0.78–0.90). This model de-
scribes the relation for a mean dose of the submandibular and sub-
lingual glands ranged from low dose to high dose (Table 3). Odd’s
ratios for each selected variable are listed in Table 4.
A negative logistic regression coefﬁcient (0.041) was found for
the mean dose of the sublingual glands and the OR was 0.96 for
each Gray increase in dose (95% CI 0.94–0.98). Elderly patients suf-
fered more from sticky saliva 6 months after treatment and pa-
tients with minor sticky saliva at baseline are more prone to
develop moderate to severe sticky saliva as compared to those
without any complaints of sticky saliva. The NTCP-value for each
individual patient can be calculated by the following logistic
regression formula:
NTCP ¼ ð1þ eSÞ1; in which
S ¼ 10:70þ ðmean dose submandibular glands  0:091Þ
þ ðage  0:107Þ þ ðbaseline sticky saliva score  1:218Þ
þ ðmean dose sublingual glands  0:041Þ
Alternatively, the NTCP-value for each individual patient can be
determined out of the nomogram for sticky saliva in Appendix C.Discussion
In this study, we investigated the signiﬁcance of radiation dose
distributions in the major and minor salivary glands in relation to
patient-rated xerostomia and sticky saliva among patients treated
with 3D-CRT. The results revealed that dose distributions in the
minor salivary glands have limited signiﬁcance for the develop-
ment of patient-rated symptoms related to salivary dysfunction
among patients treated with 3D-CRT. Besides dose distributions
in the parotid glands and the submandibular glands, only the dose
distributions in the sublingual glands were signiﬁcantly associated
with patient-rated sticky saliva. For both xerostomia and sticky
saliva the risk was higher with increasing age and pre-existing
minor complaints at baseline. This multivariate analysis of pa-
tient-rated xerostomia and sticky saliva clearly indicates that the
estimation of the risk on developing these endpoints cannot be de-
scribed by a simple univariate relationship between the dose in
one OAR and these patient-rated endpoints.
In an earlier report, Jellema et al. reported on the results of a
similar prospective study [31]. It should be noted that approxi-
mately two-third of the patients included in the study of Jellema
were also used in this study. The main differences was that in
the current study, we only included patients treated with primary
(CH)RT while patients treated with surgery were excluded. The
reason for this was that we were primarily interested in radia-
tion-induced changes and preferred to only include patients with
all salivary glands in situ. Another difference with the study of Jell-
ema et al. was that instead of using the oral cavity dose as a surro-
gate for the dose in all individual minor glands in the cheeks, soft
palate and lips, the dose distributions in all minor salivary glands
were taken into account separately.In the multivariate analysis the role of the minor salivary glands
was limited and only the sublingual glands were selected as possi-
ble predictor for patient-rated sticky saliva. In the univariate anal-
ysis for xerostomia the minor salivary glands in the soft palate
were signiﬁcantly associated with the development of patient
rated xerostomia. Similar results were found by Jellema et al. They
also found a signiﬁcant association between the doses in the oral
cavity in the univariate analysis which, however, disappeared in
the multivariate analysis if the mean parotid dose was entered in
the multivariate model [31]. It should be stressed that these pa-
tients were all treated with 3D-CRT with consequently high corre-
lations between the dose distribution parameters of the salivary
glands included in the analysis.
We decided to analyse the parotid glands, submandibular
glands, sublingual glands and the minor salivary glands separately
because the content of saliva production of these glands is different
from each other [16–22]. It is not unlikely that with IMRT, in which
the dose to the parotid glands is signiﬁcantly lower, the relative
importance of the dose distributions to the submandibular glands
and the minor glands increases. Therefore, the ﬁndings of the cur-
rent study based on patients treated with 3D-CRT should be exter-
nally validated among those treated with more advanced
techniques such as IMRT.
In the univariate analysis the treatment centre appeared as a
possible independent predictor for patient-rated xerostomia and
sticky saliva as well. The majority of patients treated in the Univer-
sity Medical Centre Groningen were treated with primary radio-
therapy for laryngeal tumours and, therefore, had relatively low
dose to the salivary glands located in the oral cavity. In contrast,
patients treated in the VU Medical Centre were mainly included
before 2007 and consisted of relatively more patients with oropha-
ryngeal and oral cavity tumours. Therefore, the patients included
from the VUMC had on average higher doses to the salivary glands.
After correcting for these differences in case mix in the multivari-
ate analysis, treatment centre itself was not signiﬁcantly associ-
ated with any of the endpoints anymore.
This study investigated the relationship between patient-rated
xerostomia and sticky saliva and the dose distributions in a variety
of salivary glands as well as other potential predictive factors. Until
now, most studies focused on the univariate relationship between
dose and stimulated parotid ﬂow [23–25]. Several NTCP models
were used to describe this relationship. The Lyman–Kutcher–Bur-
man model is currently the most commonly used NTCP model
[33,34]. This model assumes a dose volume dependent and toler-
ance dose relation between a speciﬁc OAR and a speciﬁc endpoint.
Other models also used information about dose distributions and
fractionation [35,36]. El Naqa et al. were the ﬁrst to publish a study
describing a model that was not only based on dose volume char-
acteristics, but also took other potential prognostic clinical factors
into account [32].
Some studies showed discrepancies between different end-
points related to salivary dysfunction [13,31,37–39]. Kam et al.
showed signiﬁcant differences in stimulated parotid salivary ﬂow,
whole saliva ﬂow and physician-rated xerostomia according to the
RTOG criteria in a patient population treated for head and neck
cancer with IMRT compared with a patient population treated with
two-dimensional radiotherapy (2D-RT). However, no signiﬁcant
difference in patient-rated xerostomia was found [38]. These ﬁnd-
ings suggest that patient-rated xerostomia can not only be ex-
plained by changes in the parotid ﬂow due to the radiation of the
parotid glands, but other clinical factors are of importance as well.
The parotid glands are responsible for the serous secretion of
saliva, while the other major and minor salivary glands produce
saliva with a (much) higher viscosity [16,18,40,41]. Radiation dam-
age of the acinar cells in the parotid glands diminish the saliva pro-
duction [18,8]. Due to irradiation of the submandibular glands and
92 Multivariate NTCP modelling for patient-related xerostomiaparotid glands the serous secretion of saliva is diminished more
than the mucus secretion [8,17,18,40,41]. The viscosity and pH of
the saliva will change in such a way that patients will be more
aware of sticky saliva [8,17,18,40,41].
An important ﬁnding was the inverse relationship between the
mean dose to the sublingual glands and patient-rated sticky saliva.
A possible explanation for this apparent protective effect of irradi-
ation could be related to the composition of the saliva produced by
the sublingual glands. The sublingual glands only produce highly
viscous mucous saliva [18], while irradiation of the parotid and
submandibular glands will mainly reduce production of serous sal-
iva production. Irradiation of the latter major glands with sparing
of the sublingual glands may increase the ratio between mucous
saliva and serous saliva, resulting in higher viscosity of saliva and
thus more sticky saliva. Irradiation to the sublingual glands will re-
duce the mucous saliva production resulting in a more balanced ra-
tio between mucous and serous saliva production.
Another important ﬁnding was that elderly patients have a
higher probability of suffering from xerostomia and sticky saliva
than younger patients. This is completely in agreement with the
fact that the prevalence of hyposalivation and xerostomia and
sticky saliva in a healthy population is higher in patients beyond
50 years [42]. Older patients are more likely to use medication
and to have co-morbidity that may inﬂuence and reduce the saliva
production at rest [43,44]. Therefore, older patients are more prone
to develop xerostomia and sticky saliva due to reduced secretory
reserve [45]. Only small inﬂuences on the secretion of saliva of
the salivary glands, like medication and radiation dose, are needed
to develop hyposalivation [45,46].
The development of the NTCP models for patient-rated xerosto-
mia and sticky saliva in patients treated for head and neck cancer
with 3D-CRT was the ﬁrst study in the four-step ALLEGRO ap-
proach to build validated predictive models which can be used in
the estimation which patients will beneﬁt from new radiation
techniques. The next step in the ALLEGRO project will be the vali-
dation of these models in a population treated with IMRT. It is not
self-evident that predictive models developed among patients
treated with 3D-CRT are per deﬁnition valid among patients trea-
ted with other radiation delivery techniques, such as IMRT, due
to the fact that the dose distributions in the salivary glands will
show much more variability with IMRT. This was very nicely illus-
trated by Dijkema et al. who showed that the NTCP model for sal-
ivary ﬂow among patients treated with 3D-CRT differed from that
among patients treated with IMRT [47]. Moreover, with IMRT, the
correlation between the dose distributions in the paired glands will
differ much more, which means that both glands will probably be
selected for inclusion in the multivariate analysis, which was not
the case in the present study.
Recently, we reported on the validation of a new xerostomia
questionnaire (the Groningen Radiotherapy-Induced Xerostomia
questionnaire (GRIX)), which can distinguish between patient-
rated xerostomia and sticky saliva in different situations, such as
complaints during the day or during the night [48]. As the minor
salivary glands and submandibular glands play a more important
role in production of saliva than the parotid glands during the
night, it could be hypothesized that predictive models for these
complaints change in correspondence with circadian rhythms of
salivary productions of the different salivary glands [18].
In conclusion, we developed predictive models for patient-rated
xerostomia and sticky saliva in patients treated with 3D-CRT for
head and neck cancer, using multivariate bootstrap logistic regres-
sion analysis. The results of our study illustrate that these end-
points cannot be predicted with one simple relationship between
the dose distribution in an OAR and an endpoint but that other
factors than DVH parameters are important as well. However, the
role of the dose distributions to the minor salivary glands (thesublingual glands, the salivary glands in the soft palate and in
the inner surface of the cheeks and lips) on the development of
these factors appears limited when treated with 3D-CRT. These
results should be validated among patients treated with IMRT.Acknowledgement
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